- Home
- CSLR vs ECOR Comparison
CSLR vs ECOR Comparison
Compare CSLR & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSLR
- ECOR
- Stock Information
- Founded
- CSLR 2022
- ECOR 2005
- Country
- CSLR United States
- ECOR United States
- Employees
- CSLR N/A
- ECOR N/A
- Industry
- CSLR Semiconductors
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CSLR Technology
- ECOR Health Care
- Exchange
- CSLR Nasdaq
- ECOR Nasdaq
- Market Cap
- CSLR 133.5M
- ECOR 110.4M
- IPO Year
- CSLR N/A
- ECOR 2018
- Fundamental
- Price
- CSLR $1.65
- ECOR $17.67
- Analyst Decision
- CSLR Buy
- ECOR Strong Buy
- Analyst Count
- CSLR 1
- ECOR 1
- Target Price
- CSLR $6.00
- ECOR $25.00
- AVG Volume (30 Days)
- CSLR 246.2K
- ECOR 104.7K
- Earning Date
- CSLR 01-21-2025
- ECOR 03-12-2025
- Dividend Yield
- CSLR N/A
- ECOR N/A
- EPS Growth
- CSLR N/A
- ECOR N/A
- EPS
- CSLR N/A
- ECOR N/A
- Revenue
- CSLR $40,797,000.00
- ECOR $23,327,000.00
- Revenue This Year
- CSLR $12.07
- ECOR $59.81
- Revenue Next Year
- CSLR $284.87
- ECOR $38.49
- P/E Ratio
- CSLR N/A
- ECOR N/A
- Revenue Growth
- CSLR N/A
- ECOR 74.10
- 52 Week Low
- CSLR $0.20
- ECOR $5.32
- 52 Week High
- CSLR $3.37
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- CSLR 44.30
- ECOR 55.62
- Support Level
- CSLR $1.61
- ECOR $15.83
- Resistance Level
- CSLR $1.86
- ECOR $19.43
- Average True Range (ATR)
- CSLR 0.10
- ECOR 1.19
- MACD
- CSLR -0.00
- ECOR 0.17
- Stochastic Oscillator
- CSLR 29.13
- ECOR 58.06
About CSLR Complete Solaria Inc.
Complete Solaria Inc is a solar company with unique technology and end-to-end customer offering, which includes financing, project fulfilment and customer service. Complete Solaria's digital platform together with premium solar products enable one-stop service for clean energy needs for customers wishing to make the transition to a more energy-efficient lifestyle.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.